ISL
LGND icon

Ingalls & Snyder LLC’s Ligand Pharmaceuticals LGND Stock Holding History

Ingalls & Snyder LLC’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,472
Closed -$277K – 446
2020
Q4 		$277K Buy
4,472
+833
+23% +$47.5K 0.01% 356
2020
Q3 		$216K Buy
+3,639
New +$248K 0.01% 338

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Ingalls & Snyder LLC's LGND Position: Q1 2021 in Review

Ingalls & Snyder LLC sold out of Ligand Pharmaceuticals (LGND) in Q1 2021, closing a stake of 4,472 shares — an estimated $277K sold.

Ingalls & Snyder LLC first reported a position in LGND in Q3 2020 and held it in 2 quarters. The position peaked at $277K in Q4 2020. 228 funds tracked by Wall St. Rank hold LGND as of Q1 2021.

  • Ingalls & Snyder LLC reported no remaining Ligand Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 4,472 Ligand Pharmaceuticals shares in Q1 2021, an estimated $277K.
  • Ingalls & Snyder LLC first reported a position in Ligand Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Ingalls & Snyder LLC's Ligand Pharmaceuticals position peaked at $277K in Q4 2020.
  • 228 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2021.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2021, filed 21 Apr 2021.